Cargando…

UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein

Serum levels of fully sialylated C4-binding protein (FS-C4BP) are remarkably elevated in patients with epithelial ovarian cancer (EOC) and can be used as a marker to distinguish ovarian clear cell carcinoma from endometrioma. This study aimed to develop a stable, robust and reliable liquid chromatog...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanabe, Kazuhiro, Matsuo, Koji, Miyazawa, Masaki, Hayashi, Masaru, Ikeda, Masae, Shida, Masako, Hirasawa, Takeshi, Sho, Ryuichiro, Mikami, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534807/
https://www.ncbi.nlm.nih.gov/pubmed/29265394
http://dx.doi.org/10.1002/bmc.4180
_version_ 1783590367921176576
author Tanabe, Kazuhiro
Matsuo, Koji
Miyazawa, Masaki
Hayashi, Masaru
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Sho, Ryuichiro
Mikami, Mikio
author_facet Tanabe, Kazuhiro
Matsuo, Koji
Miyazawa, Masaki
Hayashi, Masaru
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Sho, Ryuichiro
Mikami, Mikio
author_sort Tanabe, Kazuhiro
collection PubMed
description Serum levels of fully sialylated C4-binding protein (FS-C4BP) are remarkably elevated in patients with epithelial ovarian cancer (EOC) and can be used as a marker to distinguish ovarian clear cell carcinoma from endometrioma. This study aimed to develop a stable, robust and reliable liquid chromatography–hybrid mass spectrometry (UPLC-MS/MS) based diagnostic method that would generalize FS-C4BP as a clinical EOC biomarker. Glycopeptides derived from 20 μL of trypsin-digested serum glycoprotein were analyzed via UPLC equipped with an electrospray ionization time-of-flight mass spectrometer. This UPLC-MS/MS-based diagnostic method was optimized for FS-C4BP and validated using sera from 119 patients with EOC and 127 women without cancer. A1958 (C4BP peptide with two fully sialylated biantennary glycans) was selected as a marker of FS-C4BP because its level in serum was highest among FS-C4BP family members. Preparation and UPLC-MS/MS were optimized for A1958, and performance and robustness were significantly improved relative to our previous method. An area under the curve analysis of the FS-C4BP index receiver operating characteristic curve revealed that the ratio between A1958 and A1813 (C4BP peptide with two partially sialylated biantennary glycans) reached 85%. A combination of the FS-C4BP index and carbohydrate antigen-125 levels further enhanced the sensitivity and specificity.
format Online
Article
Text
id pubmed-7534807
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-75348072020-10-05 UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein Tanabe, Kazuhiro Matsuo, Koji Miyazawa, Masaki Hayashi, Masaru Ikeda, Masae Shida, Masako Hirasawa, Takeshi Sho, Ryuichiro Mikami, Mikio Biomed Chromatogr Article Serum levels of fully sialylated C4-binding protein (FS-C4BP) are remarkably elevated in patients with epithelial ovarian cancer (EOC) and can be used as a marker to distinguish ovarian clear cell carcinoma from endometrioma. This study aimed to develop a stable, robust and reliable liquid chromatography–hybrid mass spectrometry (UPLC-MS/MS) based diagnostic method that would generalize FS-C4BP as a clinical EOC biomarker. Glycopeptides derived from 20 μL of trypsin-digested serum glycoprotein were analyzed via UPLC equipped with an electrospray ionization time-of-flight mass spectrometer. This UPLC-MS/MS-based diagnostic method was optimized for FS-C4BP and validated using sera from 119 patients with EOC and 127 women without cancer. A1958 (C4BP peptide with two fully sialylated biantennary glycans) was selected as a marker of FS-C4BP because its level in serum was highest among FS-C4BP family members. Preparation and UPLC-MS/MS were optimized for A1958, and performance and robustness were significantly improved relative to our previous method. An area under the curve analysis of the FS-C4BP index receiver operating characteristic curve revealed that the ratio between A1958 and A1813 (C4BP peptide with two partially sialylated biantennary glycans) reached 85%. A combination of the FS-C4BP index and carbohydrate antigen-125 levels further enhanced the sensitivity and specificity. 2018-01-23 2018-05 /pmc/articles/PMC7534807/ /pubmed/29265394 http://dx.doi.org/10.1002/bmc.4180 Text en This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Tanabe, Kazuhiro
Matsuo, Koji
Miyazawa, Masaki
Hayashi, Masaru
Ikeda, Masae
Shida, Masako
Hirasawa, Takeshi
Sho, Ryuichiro
Mikami, Mikio
UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title_full UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title_fullStr UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title_full_unstemmed UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title_short UPLC-MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4-binding protein
title_sort uplc-ms/ms based diagnostics for epithelial ovarian cancer using fully sialylated c4-binding protein
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534807/
https://www.ncbi.nlm.nih.gov/pubmed/29265394
http://dx.doi.org/10.1002/bmc.4180
work_keys_str_mv AT tanabekazuhiro uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT matsuokoji uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT miyazawamasaki uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT hayashimasaru uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT ikedamasae uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT shidamasako uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT hirasawatakeshi uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT shoryuichiro uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein
AT mikamimikio uplcmsmsbaseddiagnosticsforepithelialovariancancerusingfullysialylatedc4bindingprotein